ARTICLE | Emerging Company Profile
B-ing persistent
How Aleta’s CAR T cell platform could direct CD19 CARs to any tumor type
March 17, 2017 6:47 PM UTC
Aleta Biotherapeutics Inc. is extending the use of CD19-targeting CAR T cells by coating non-B cell tumors with the antigen.
President and CSO Paul Rennert told BioCentury the key to effective CAR T cell therapies is targeting a plentiful tumor antigen that can trigger wide and persistent expansion of the T cells. ...
BCIQ Company Profiles